High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege

Ager, C. R., Boda, A., Rajapakshe, K., Lea, S. T., Di Francesco, M. E., Jayaprakash, P., Slay, R. B., Morrow, B., Prasad, R., Dean, M. A., Duffy, C. R., Coarfa, C., Jones, P., & Curran, M. A. (2021). High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. Journal for ImmunoTherapy of Cancer, 9(8), e003246. https://doi.org/10.1136/jitc-2021-003246
Authors:
Casey R Ager
Akash Boda
Kimal Rajapakshe
Spencer Thomas Lea
Maria Emilia Di Francesco
Priyamvada Jayaprakash
Ravaen B Slay
Brittany Morrow
Rishika Prasad
Meghan A Dean
Colm R Duffy
Cristian Coarfa
Philip Jones
Michael A Curran
Affiliated Authors:
Casey R Ager
Columbia Affiliation:
Subjects:
Innate Immunity to Viral Infection (OpenAlex Topic)
Macrophage Activation and Polarization (OpenAlex Topic)
Role of STAT3 in Cancer Inflammation and Immunity (OpenAlex Topic)
Immunotherapy (MeSH)
Membrane Proteins (MeSH)
Myeloid-Derived Suppressor Cells (MeSH)
Pancreatic Neoplasms (MeSH)
Author Keywords:
alarmins
immunity
immunotherapy
innate
myeloid-derived suppressor cells
tumor microenvironment
elink
Publication Type:
Article
Unique ID:
10.1136/jitc-2021-003246
PMID:
34341132
DOI:
10.1136/jitc-2021-003246
Journal:
Journal for ImmunoTherapy of Cancer
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View OpenAlex Record

Record Created: